Thermo Fisher Scientific (TMO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
397.0mn → 378.0mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
steady at 3.4% of revenue (+8.9% YoY).
$3.6B returned vs $6.3B of FCF in FY25. Buybacks + dividends covered by cash flow.
15¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Over this window: gross 50.1% → 40.9%. Net margin 15.0% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 47,351.0 | 44,556.0 | 42,879.0 | 42,857.0 | 44,915.0 | 39,211.0 | ▲3.9% | +3.2% |
Cost of revenue | 27,897.0 | 26,318.0 | 25,177.0 | 25,757.0 | 25,944.0 | 19,573.0 | ▲4.5% | +7.7% |
Gross profit | 19,454.0 | 18,238.0 | 17,702.0 | 17,100.0 | 18,971.0 | 19,638.0 | ▲3.0% | −1.8% |
Research & development | 1,405.0 | 1,397.0 | 1,390.0 | 1,337.0 | 1,471.0 | 1,406.0 | ▲0.5% | −0.2% |
Selling, general & admin | 9,187.0 | 8,732.0 | 8,595.0 | 8,445.0 | 8,993.0 | 8,007.0 | ▲1.6% | +2.2% |
Total operating expenses | 10,985.0 | 10,491.0 | 10,364.0 | 10,241.0 | 10,578.0 | 9,610.0 | ▲1.2% | +2.2% |
Operating incomefeeds ROC rank | 8,468.0 | 7,746.0 | 7,337.0 | 6,859.0 | 8,393.0 | 10,028.0 | ▲5.6% | −6.3% |
Other income, net | −569.0 | −438.0 | −300.0 | −561.0 | −558.0 | −1,187.0 | — | — |
Pretax income | 7,899.0 | 7,308.0 | 7,037.0 | 6,298.0 | 7,835.0 | 8,841.0 | ▲3.9% | −4.6% |
Income tax | 742.0 | 547.0 | 657.0 | 284.0 | 703.0 | 1,109.0 | ▼16.7% | −16.2% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 7,073.0 | 6,704.0 | 6,335.0 | 5,995.0 | 6,950.0 | 7,725.0 | ▲5.8% | −3.5% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 18.96 | 17.74 | 16.53 | 15.45 | 17.63 | 19.46 | ▲7.3% | −2.3% |
Diluted shares (mn) | 371.00 | 378.00 | 383.00 | 388.00 | 394.00 | 397.00 | ▼1.3% | −1.2% |
| Margins | ||||||||
Gross margin22nd pct in Healthcare | 41.1% | 40.9% | 41.3% | 39.9% | 42.2% | 50.1% | ▼0.4pp | −9.2pp |
Operating margin | 17.9% | 17.4% | 17.1% | 16.0% | 18.7% | 25.6% | ▲0.3pp | −8.2pp |
Net margin78th pct in Healthcare | 14.9% | 15.0% | 14.8% | 14.0% | 15.5% | 19.7% | ▲0.3pp | −4.7pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Thermo Fisher Scientific's revenue last fiscal year?
Thermo Fisher Scientific reported revenue of $44.6B in fiscal 2025, up 3.9% from fiscal 2024.
What was Thermo Fisher Scientific's net income?
Thermo Fisher Scientific reported net income of $6.7B in fiscal 2025, a net margin of 15.0%.

